Clinical Epidemiology and Ageing

[Determinants of the cost of initiation of insulin therapy type 2 diabetic patients in France: possible approaches to optimization].

Hanaire H, Attali C, Lecointre B, Fraysse M, Gouet D, Babel M-R, Charbonnel B, Sarkozy F, Gourmelen J, Detournay B Sante Publique. 2016;28(6):781-789.

<p>Increased costs cannot be exclusively attributed to the consequences of insulin prescription. Any initiative designed to&#160;accelerate acquisition of patient autonomy would be likely to reduce the costs observed after switching to insulin, provided this initiative is adapted to the patient&#8217;s health profile, diabetes history and available medical resources.</ce:para>.</p>

MeSH terms: Aged; Costs and Cost Analysis; Diabetes Mellitus, Type 2; France; Humans; Hypoglycemic Agents; Infant; Insulin; Male; Middle Aged